International Journal of Infectious Diseases (2007) 11, 450—453

http://intl.elsevierhealth.com/journals/ijid

Bloodstream in febrile neutropenic patients at a tertiary care center in Lebanon: a view of the past decade

Zeina A. Kanafani a, Ghenwa K. Dakdouki b, Khalil I. El-Chammas c, Shaker Eid d, George F. Araj e, Souha S. Kanj f,* a Division of Infectious Diseases, Duke University Medical Center, Durham, NC, USA b Hammoud Hospital, Sidon, Lebanon c Department of Pediatrics, American University of Beirut Medical Center, Beirut, Lebanon d Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon e Department of Pathology & Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon f Division of Infectious Diseases, American University of Beirut Medical Center, Cairo Street, PO Box 113-6044, Hamra 110 32090, Beirut, Lebanon

Received 10 October 2006; accepted 11 December 2006 Corresponding Editor: William Cameron, Ottawa, Canada

KEYWORDS Summary Neutropenic ; Objectives: Previous studies from Lebanon have shown Gram-negative organisms to be the Bacteremia; predominant agents in febrile neutropenic patients. The objective of this study was to evaluate Gram-negative ; the most current epidemiological trends among patients with neutropenic fever. Lebanon Methods: This prospective observational cohort study, the largest to date in the country, was conducted at the American University of Beirut Medical Center between January 2001 and December 2003, with the objective of describing the characteristics of patients with neutropenic fever and to assess temporal trends. Results: We included 177 episodes of neutropenic fever. The most common underlying malignancy was lymphoma (42.4%). Gastrointestinal and abdominal infections were predominant (31.6%) and 23.7% of cases represented fever of unknown origin. Gram-negative organisms were responsible for 78.8% (26/33) of compared to 33.3% (11/33) with Gram-positive organisms. The in-hospital mortality rate in this study (12.1%) was considerably lower than in previous years. Conclusions: Gram-negative organisms are persistently predominant in our center.In a developing country like Lebanon with limited resources, lower mortality rates commensurate with worldwide reports were successfully achieved in this high-risk patient population. Protocols and guidelines should be adapted to the characteristics of individual institutions to ensure delivery of appropriate care to febrile neutropenic patients. # 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

* Corresponding author. Tel.: +961 1 350000x5381; fax: +961 1 370814. E-mail address: [email protected] (S.S. Kanj).

1201-9712/$32.00 # 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. doi:10.1016/j.ijid.2006.12.008 Bloodstream infections in febrile neutropenic patients 451

Introduction guidelines of the Infectious Diseases Society of America (IDSA) on neutropenic fever.7 A focal infection was consid- Infectious processes continue to pose a problem of consider- ered present if the patient had symptoms, radiographic able magnitude that impacts the quality of life and survival of evidence, or a positive culture suggestive of infection at a cancer patients presenting with neutropenic fever.1 Over the particular site. Patients were followed daily throughout their past decade, advances in the field have been counterba- hospital stay and information was collected in a prospective lanced by a rising number of immunosuppressed patients with fashion. a multitude of new risk factors for infection and an ongoing emergence of antimicrobial resistance.2 Statistical analysis In recent years, a shift in the epidemiology of infections in febrile neutropenic patients in several parts of the world has Data were entered into a database using SPSS 11.0 for been observed towards predominance of Gram-positive Windows (SPSS Inc, Chicago, IL, USA). Bivariate analysis infections.3 This trend has not been corroborated in prior was performed using the Chi-square test for categorical studies from Lebanon where Gram-negative organisms still variables and the independent samples t-test for continuous occupied the biggest share of infecting agents, and where variables. Variables that were significant on bivariate analy- mortality rates were significant.4—6 In this observational sis were entered into a multivariate logistic regression model cohort study, we describe the characteristics of patients using Stata 7.0 (Stata Corporation, College Station, TX, USA). presenting with febrile neutropenic episodes during the first three years of the 21st century, and compare the results to Ethical considerations two studies published previously from the same institution to assess temporal trends over the past decade. The study was approved by the Institutional Review Board at AUBMC. Since this was an observational study, informed Materials and methods consent was waived.

Study location and patients Results

The study was conducted between January 2001 and Decem- Patient characteristics ber 2003 at the American University of Beirut Medical Center (AUBMC), a 400-bed teaching hospital in Lebanon. Eligible During the study period, we identified 177 episodes of neu- patients were individuals at least 13 years of age with tropenic fever in 116 patients. Patient age ranged from 15 to neutropenic fever following . Patients were 86 years, with a mean of 47.8 years. The most common included more than once if they developed a second episode underlying malignancy was lymphoma (42.4%), followed by of neutropenic fever during the study period. The definitions leukemia (34.5%), and solid tumors (16.4%). Prophylactic of fever and were based on the latest published had been given in 32 cases (18.1%).

Table 1 Trends in bloodstream infections in neutropenic fever in Lebanon

Organism 1995—98 (N = 104) 1999 (N = 50) 2001—04 (N = 177) Gram-negative organisms 18 (17.3) 9 (18.0) 26 (14.7) Escherichia coli 9 (8.7) 4 (8.0) 17 (9.6) 5 (4.8) 3 (6.0) 4 (2.3) Klebsiella spp 2 (1.9) 0 3 (1.7) Enterobacter spp 0 1 (2.0) 2 (1.1) Acinetobacter spp 1 (1.0) 0 0 Salmonella enteritidis 1 (1.0) 0 0 Bacteroides spp 0 1 (2.0) 0 Gram-positive organisms 12 (11.5) 5 (10.0) 11 (6.2) CoNS 6 (5.8) 1 (2.0) 8 (4.5) MSSA 2 (1.9) 0 0 MRSA 2 (1.9) 3 (6.0) 0 Viridans streptococcus 1 (1.0) 1 (2.0) 1 (0.6) Group D streptococcus 0 0 1 (0.6) Enterococcus spp 1 (1.0) 0 0 Bacillus spp 0 0 1 (0.6) Candida albicans 0 1 (2.0) 2 (1.1) Polymicrobial 0 0 5 (2.8) No growth 74 (71.2) 35 (70.0) 144 (81.4) CoNS, coagulase-negative staphylococci; MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus. 452 Z.A. Kanafani et al.

Description of neutropenic fever episodes describing 50 consecutive episodes.6 The current study was carried out with the intention of testing the persistence of The mean duration of neutropenia in our patient population the previously observed findings and to describe in more was 7.2 days. The majority of patients (62.2%) had severe detail the characteristics and outcome of patients with neutropenia, as defined by an absolute count less neutropenic fever. than 100 cells/mm3. Neutropenic episodes were labeled as The etiology of bacteremia in febrile neutropenic patients clinically documented infections (46.9%), microbiologically has witnessed momentous changes in the past few decades. documented infections (29.4%), or fever of unknown origin Whereas in the 1950s the major culprit was Staphylococcus (23.7%). The most common source of infection was the abdo- aureus, Gram-negative organisms, particularly P.aeruginosa, men and gastrointestinal tract (31.6%), followed by the had the upper hand in the two decades that followed. How- respiratory system (20.9%). ever, Gram-positive organisms had re-emerged as principal players throughout the 1990s, spearheaded by coagulase- 8,9 Bloodstream infections negative staphylococci. Yet infections in the setting of neutropenic fever are proving to be quite dynamic, as a Positive blood cultures were documented in 33 episodes of new trend is now starting to come into view, where Gram- 10—12 neutropenic fever (18.6%) (Table 1). This represents a lower negative organisms seem to be resurfacing. Several rate compared to previous years (30% in 1999 and 28.8% in factors have been implicated in this ever-changing epide- 1995—98). Gram-negative organisms were responsible for 26 miology, namely the increased placement of indwelling of 33 documented bloodstream infections compared to 11 of catheters, the administration of antimicrobial prophylaxis, 33 infections with Gram-positive organisms. The rate of the nature of chemotherapeutic regimens currently in use, as Gram-negative bloodstream infections exceeded that of well as several environmental conditions that are still poorly 3,7,9,13,14 Gram-positive bloodstream infections (14.7% vs. 6.2%), simi- elucidated. lar to the trend seen in the earlier studies, although to a In Lebanon, the pattern of infecting organisms in febrile different degree. Whereas in the period from 1995 to 1998 neutropenic patients has been rather static in direction but 4—6 the ratio of Gram-positive to Gram-negative infections was not in magnitude. Data from this country extending over 1.5:1, this ratio became 1.8:1 in 1999, and in the current the past decade have consistently found a higher prevalence study it was 2.4:1. Among the Gram-negative organisms, of Gram-negative infections. Not only did we show that Escherichia coli has been consistently the most commonly Gram-negative organisms caused 26 of 33 bloodstream infec- isolated organism, followed by Pseudomonas aeruginosa. tions in the current study, we also noted that the gap is Similarly in the Gram-positive bacteremia group, coagu- widening between Gram-positive and Gram-negative infec- lase-negative staphylococci continue to represent the major- tions over time. ity of isolates. On the other hand, there were five episodes of This trend does not seem to be shared by other countries polymicrobial bloodstream infections in the latest patient in the region, where all studies have confirmed the predo- 15—18 sample, which is a new and unique feature compared to the minance of Gram-negative infections. However, one earlier cohorts. report from Pakistan has recently shown a slight preponder- ance of infections with Gram-negative organisms (53%) com- 19 Treatment pared to Gram-positive organisms. A possible explanation of the observed high incidence of was the antimicrobial agent most commonly used Gram-negative infections in Lebanon is the relatively low as first-line therapy in the studied episodes of neutropenic proportion of patients with indwelling catheters, although fever (50.3%), followed by ceftazidime (36.7%) and pipera- increased prevalence of Gram-positive infections has also been reported from other centers where long-term catheters cillin/tazobactam (10.2%). Glycopeptides were used as addi- 3 tional first-line empiric treatment in 37 cases (20.9%). are not commonly used. Another probable contributing Antifungal agents were used in 101 cases (57.1%), fluconazole factor is the low proportion of patients receiving antimicro- being used the most. bial prophylaxis compared to other studies. Prophylactic regimens containing old generation quinolones lack effective coverage against Gram-positive organisms and thus predis- Outcome pose to breakthrough Gram-positive infections. However, such regimens also promote the emergence of resistance Fourteen episodes of neutropenic fever (7.9%) led to a fatal among Gram-negative pathogens. At a time when there is outcome, giving an in-hospital mortality rate of 12.1%. On a dire need to contain the rising antimicrobial resistance in multivariate analysis, the only two variables associated with Gram-negative organisms in Lebanon,20 and in the absence of increased in-hospital mortality were treatment modification a clear and consistent survival benefit, the decision to admin- for clinical deterioration (OR = 21.26; 95% CI 4.14—109.25) ister antimicrobial prophylaxis in afebrile neutropenic and duration of neutropenia (OR = 1.14; 95% CI 1.03—1.26). patients should take into consideration the risks and benefits of this practice. Discussion We found an in-hospital mortality of 12.1% in the present analysis compared to 20% in the two previous studies at Until recently, the epidemiology of neutropenic fever in AUBMC.5,6 These results are still slightly higher but more Lebanon has been poorly described. Between 1995 and comparable to recent published data documenting mortality 1998, a prospective analysis of 104 episodes of neutropenic rates ranging between 4 and 7%.19,21,22 The decrease in the fever was reported,5 and in 1999, a follow-up study was done proportion of high-risk patients with leukemia in favor of Bloodstream infections in febrile neutropenic patients 453 patients with lymphoma and solid tumors, usually classified in 9. Zinner SH. Changing epidemiology of infections in patients with the intermediate or low-risk group, could partially account neutropenia and cancer: emphasis on Gram-positive and resis- for the observed decrease in in-hospital mortality. None- tant bacteria. Clin Infect Dis 1999;29:490—4. theless, in a developing country like Lebanon with limited 10. Aksu G, Ruhi MZ, Akan H, Bengisun S, Ustun C, Arslan O, et al. Aerobic bacterial and fungal infections in peripheral blood stem resources, a lower in-hospital mortality rate commensurate cell transplants. Transplant 2001;27:201—5. with worldwide reports was achieved in this high-risk popula- 11. Gaytan-Martinez J, Mateos-Garcia E, Sanchez-Cortes E, Gonzalez- tion. Llaven J, Casanova-Cardiel LJ, Fuentes-Allen JL. Microbiological findings in febrile neutropenia. Arch Med Res 2000;31:388—92. Conclusions 12. Haupt R, Romanengo M, Fears T, Viscoli C, Castagnola E. Inci- dence of septicaemias and invasive mycoses in children under- going treatment for solid tumours: a 12-year experience at a In this third study from AUBMC describing the characteristics single Italian institution. Eur J Cancer 2001;37:2413—9. of patients with neutropenic fever, a continually increasing 13. Jones RN, Beach ML, Pfaller MA. Spectrum and activity of three prevalence of Gram-negative infections was observed. This contemporary fluoroquinolones tested against Pseudomonas aer- divergence from the worldwide reported data that denotes a uginosa isolates from urinary tract infections in the SENTRY predominance of Gram-positive infections underscores the Antimicrobial Surveillance Program (Europe and the Americas; importance of tailoring and revising international protocols 2000): more alike than different!. Diagn Microbiol Infect Dis and guidelines to correspond to the unique composition of 2001;41:161—3. our patient population. The considerable reduction in in- 14. Raje NS, Rao SR, Iyer RS, Kelkar RS, Pai SK, Nair CN, et al. hospital mortality that has been achieved over the years Infection analysis in acute lymphoblastic leukemia: a report of attests to the success of this strategy. 499 consecutive episodes in India. Pediatr Hematol Oncol 1994;11:271—80. Conflict of interest: No conflict of interest to declare. 15. al-Bahar S, Pandita R, Dhabhar BN, al-Bahar E. Febrile neutro- penia in cancer patients in Kuwait: microbial spectrum and References outcome. Support Care Cancer 1994;2:400—2. 16. al-Fawaz IM, Kambal AM, al-Rabeeah AA, al-Rasheed SA, al-Eissa 1. Viscoli C, Varnier O, Machetti M. Infections in patients with YA, Familusi JB. Septicaemia in febrile neutropenic children with febrile neutropenia: epidemiology, microbiology, and risk stra- cancer in Saudi Arabia. J Hosp Infect 1991;18:307—12. tification. Clin Infect Dis 2005;40(Suppl 4):S240—5. 17. Mahmood S, Revesz T, Mpofu C. Febrile episodes in children with 2. Klastersky J. Management of fever in neutropenic patients with cancer in the United Arab Emirates. Pediatr Hematol Oncol different risks of complications. Clin Infect Dis 2004;39(Suppl 1): 1996;13:135—42. S32—7. 18. Santhosh-Kumar CR, Ajarim DS, Harakati MS, al Momen AK, al 3. Ramphal R. Changes in the etiology of bacteremia in febrile Mohareb F, Zeitany RG. Ceftazidime and amikacin as empiric neutropenic patients and the susceptibilities of the currently treatment of febrile episodes in neutropenic patients in Saudi isolated pathogens. Clin Infect Dis 2004;39(Suppl 1): Arabia. J Infect 1992;25:11—9. S25—31. 19. Khan MA, Siddiqui BK, Shamim A, Yosuf MA, Ahmed U, Zakiullah 4. Ghosn M, Dagher E, Nasr F, Chahine G, Taleb N, Nasnas R, et al. N, et al. Emerging bacterial resistance patterns in febrile neu- Infections in cancer patients with granulocytopenia. Retrospec- tropenic patients: experience at a tertiary care hospital in tive studies of 59 febrile episodes with hospitalization. J Med Pakistan. J Pak Med Assoc 2004;54:357—60. Liban 1994;42:117—22. 20. Kanafani ZA, Mehio-Sibai A, Araj GF, Kanaan M, Kanj SS. Epide- 5. Hamzeh F, Kanj SS, Uwaydah M. Febrile neutropenia in cancer miology and risk factors for extended-spectrum beta-lactamase- patients in a tertiary care medical center in Lebanon: microbial producing organisms: a case control study at a tertiary care spectrum and outcome. J Med Liban 2000;48:136—42. center in Lebanon. Am J Infect Control 2005;33:326—32. 6. Kanj SS, Adel N, Araj GF. The continued prevalence of Gram- 21. Cherif H, Bjorkholm M, Engervall P, Johansson P, Ljungman P, negative infections in febrile neutropenic patients in Lebanon. Hast R, et al. A prospective, randomized study comparing cefe- Comparison with studies from the Middle East. BMJ (Middle East) pime and —cilastatin in the empirical treatment of 2001;8:6—13. febrile neutropenia in patients treated for haematological 7. Hughes WT, Armstrong D, Bodey GP,Bow EJ, Brown AE, Calandra malignancies. Scand J Infect Dis 2004;36:593—600. T, et al. 2002 guidelines for the use of antimicrobial agents in 22. Rossini F, Terruzzi E, Verga L, Larocca A, Marinoni S, Miccolis I, neutropenic patients with cancer. Clin Infect Dis 2002;34: et al. A randomized clinical trial of ceftriaxone and amikacin 730—51. versus tazobactam and amikacin in febrile patients 8. Oppenheim BA. The changing pattern of infection in neutropenic with hematological neoplasia and severe neutropenia. Support patients. J Antimicrob Chemother 1998;41(Suppl D):7—11. Care Cancer 2005;13:387—92.